Trial · NCT05096884
Post-Acute Sequelae of Coronavirus-19 (COVID-19) With Dyspnea on Exertion And Associated TaChycardia TrEatment Study
NCT05096884, Early phase 1, Terminated, Hackensack Meridian Health; results first posted 2024-12-03
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Post-Acute Sequelae of Coronavirus-19 (COVID-19) With Dyspnea on Exertion And Associated TaChycardia TrEatment Study. Trials, record NCT05096884. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05096884
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Post-Acute Sequelae of Coronavirus-19 (COVID-19) With Dyspnea on Exertion And Associated TaChycardia TrEatment Study
- NCT number
- NCT05096884
- Status
- Terminated
- Phases
- Early phase 1
- Enrollment
- 14 participants, actual
- Lead sponsor
- Hackensack Meridian Health
- Conditions
- Tachycardia, Dyspnea, COVID-19
- Interventions
- Metoprolol Succinate
- First posted
- 2021-10-27
- Last updated
- 2024-12-03
- Results first posted
- 2024-12-03
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in 6 Minute Walk Test at the End of Treatment Period | 12 weeks from baseline walk test | To assess the reduction of symptoms in patients with PASC Dyspnea on Exertion (DOE) and associated tachycardia when treated with beta blockers as captured in patients walk test. Walk test will be performed at day 1 (baseline) and at 2-4 weeks post treatment completion which consists of 8 weeks metoprolol succinate (approximately 12 weeks from baseline). |
| Primary | Change in Zva Measurement at the End of Treatment Period | 12 weeks from baseline transthoracic echocardiogram (TTE). | To assess the reduction of symptoms in patients with PASC Dyspnea on Exertion (DOE) and associated tachycardia when treated with beta blockers as captured in Zva measurement calculated from patient's TTE (transthoracic echocardiogram). TTE (and Zva) will be performed at day 1 (baseline) and at 2-4 weeks post treatment completion which consists of 8 weeks metoprolol succinate (approximately 12 weeks from baseline). |
| Secondary | Change in Minnesota Living With Heart Failure Score at the End of Treatment Period | 12 weeks from baseline | Subjective improvement in Dyspnea on Exertion (DOE), tachycardia and well being score as measured by the Minnesota Living with Heart Failure. The Minnesota Living with Heart Failure questionnaire will be administered at day 1 (baseline) and at 2-4 weeks post treatment completion which consists of 8 weeks metoprolol succinate (approximately 12 weeks from baseline). Minnesota Living with Heart Failure questionnaire is a 21-item questionnaire with each item having a 6 point Likert scale (0-5), Zero represents "No symptom" and 5 represents high intensity of symptom. The questionnaire has 3 dimension and they measure Physical, socio-economic and emotional/psychological aspects respectively. The total score is the sum of all item responses for total and dimension scores. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in 6 Minute Walk Test at the End of Treatment Period | 12 weeks from baseline walk test | Total distance walked within 6 minutes | meters | MEAN |
| PRIMARY | Change in Zva Measurement at the End of Treatment Period | 12 weeks from baseline transthoracic echocardiogram (TTE). | Zva measurement in (mmHg mL\^-1) m\^2 | (mmHg mL^-1) m^2 | MEAN |
| SECONDARY | Change in Minnesota Living With Heart Failure Score at the End of Treatment Period | 12 weeks from baseline | Mean of total score in the Minnesota Living with Heart Failure. | score on a scale | MEAN |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in 6 Minute Walk Test at the End of Treatment Period | Study Arm - Metoprolol Succinate. | Distance walked at baseline | 275 | Standard Deviation 76 | meters |
| Change in 6 Minute Walk Test at the End of Treatment Period | Study Arm - Metoprolol Succinate. | Distance walked post treatment | 339 | Standard Deviation 76 | meters |
| Change in Zva Measurement at the End of Treatment Period | Study Arm - Metoprolol Succinate. | Zva at baseline | 4.24 | Standard Deviation 0.83 | (mmHg mL^-1) m^2 |
| Change in Zva Measurement at the End of Treatment Period | Study Arm - Metoprolol Succinate. | Zva post treatment | 3.70 | Standard Deviation 0.72 | (mmHg mL^-1) m^2 |
| Change in Minnesota Living With Heart Failure Score at the End of Treatment Period | Study Arm - Metoprolol Succinate. | Minnesota Living with Heart Failure scale at baseline | 74 | Standard Deviation 16 | score on a scale |
| Change in Minnesota Living With Heart Failure Score at the End of Treatment Period | Study Arm - Metoprolol Succinate. | Minnesota Living with Heart Failure scale post treatment | 52 | Standard Deviation 18 | score on a scale |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Study Arm - Metoprolol Succinate. | 14 | |
| Overall Study | COMPLETED | Study Arm - Metoprolol Succinate. | 10 | |
| Overall Study | NOT COMPLETED | Study Arm - Metoprolol Succinate. | 4 |
Source ClinicalTrials.gov
Adverse events1
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Symptomatic hypotension | Cardiac disorders | Study Arm - Metoprolol Succinate. | 1 | 10 | 1 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Study Arm - Metoprolol Succinate. | 0 | 10 |
| Total, other adverse events | Study Arm - Metoprolol Succinate. | 1 | 10 |
| Total, serious adverse events | Study Arm - Metoprolol Succinate. | 0 | 10 |
Source ClinicalTrials.gov
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05096884
GET https://conductscience.org/api/trials/v1/NCT05096884/registered